METTL5 has been confirmed to be overexpressed in a variety of tumors and affects patient prognosis, such as hepatocellular carcinoma (7, 18), Intrahepatic cholangiocarcinoma (ICC) (8), and breast cancer (14). Here, METTL5 is linked to hepatocellular carcinoma.